Honored at the White House Privo Technologies receives the 2016 National Tibbetts Award

Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to the Small Business Innovation Research (SBIR) program. The SBIR program stated “We are proud to recognize your company’s outstanding work that has contributed so greatly to the success of the SBIR program.” Privo would like to congratulate it’s team for their hard work and dedication to the company. On January 10, 2017, Privo’s CEO and Founder, Dr. Manijeh Goldberg, received the honor at the White House during a special awards ceremony.

Go to article
January 10, 2017

Share this post

Author

Related Posts

18Jun

BIO International Convention 2021

Privo Technologies, Inc.  attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year... read more

13Sep

Privo receives Commercialization Award from the National Cancer Institute

Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston and... read more

04Feb

Privo Technologies, Inc. To Present at the 24th Annual BIO CEO & Investor Conference

Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more

10Dec

Privo Technologies Opens New Lab Facility in Peabody, MA

Privo Technologies expands to a new 3,000 square foot facility just outside of Boston, MA. Located at 200 Corporate Place,... read more

19Aug

Privo Technologies Named Winner of AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition 2020

PEABODY, Mass., Sept. 24, 2020 -- Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal... read more

02Dec

MIT Selects Privo Technologies To Showcase the Company’s Groundbreaking Cancer Therapy in Japan and Korea.

Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its... read more

10Dec

Privo Technologies receives 2015 TechConnect Innovation Award

Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was rated... read more

01Apr

National Cancer Institute awards

Privo a $2.5M grant to optimize it lead product and prepare for its IND. read more

25Feb

Privo Technologies, Inc. Awarded $2.5M from National Cancer Institute for its Intraoperative Treatment of Solid Tumors

Peabody, MA — Privo Technologies, Inc. (“Privo”, “the Company”), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments announced... read more

24Oct

Privo Technologies begins FDA Approved Clinical Trials

BOSTON, Oct. 24, 2018 /PRNewswire/ -- Privo Technologies was granted the green light from the FDA and several hospitals this summer to... read more

Contact Us
close slider

Contact Us